Why the Respiri (ASX:RSH) share price opened higher today

The Respiri Ltd (ASX:RSH) share price opened higher today after the company announced plans to launch its Wheezo app in the United Kingdom.

| More on:
medical asx share price represented by doctor giving thumbs up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Respiri Ltd (ASX: RSH) shares were on the move this morning after the company announced it will be launching its Wheezo brand in the United Kingdom. The Respiri share price opened around 3% higher following the news. However, at the time of writing, the company's shares have retreated back to 16 cents, flat for the day so far.

The software-as-a-service (Saas) company also advised today that two new executives will be joining its board as strategic advisors.

Let's look further into the company's announcements.

Wheezo UK launch

The Respiri share price was temporarily boosted today after the company stated it plans to launch Wheezo in the UK. The combination app and device product aims to help those with asthma manage the condition. The company said it is on track to launch in the UK market in late 2021.

This comes after Respiri's news on Tuesday that Wheezo has received United States Food and Drug Administration (FDA) clearance.

Respiri is in discussions with multinational pharmaceutical company Cipla and other potential partners ahead of Wheezo's UK launch.

Further, Respiri states it's in discussions with leading clinicians in the UK regarding the company's participation as a technology partner in multiple, large, asthma-related studies. These studies are expected to provide evidence for the use of asthma therapeutics and the role of digital technologies in the management of paediatric asthma.

The company says better asthma management has the potential to lead to improved outcomes and quality of life for those with the condition.

Advisor appointments to Respiri board

In further news impacting the Respiri share price this morning, the company also announced it has recently appointed two new advisors to its board.

Dr Andrew Weekes and Dr Mark Levy will aid the company in its UK launch, according to the announcement.

Dr Weekes is the country medical director for Australia of GlaxoSmithKline (NYSE: GSK). Respiri states GlaxoSmithKline is a leading global player in respiratory diseases. Dr Weekes will provide advice to Respiri's board regarding Wheezo's commercialisation, its clinical development and other subjects.    

Dr Levy has been appointed as an advisor for the UK. He has been a member of the Global Initiative for Asthma executive board since 2009. Respiri CEO Marjan Mikel said Dr Levy has provided the board with advice and introductions ahead of its UK launch.

Respiri share price snapshot

The Respiri share price is having a stellar year on the ASX and is currently up by 23.08% year to date. It is also up by nearly 83% over the last 12 months.

The company has a market capitalisation of around $115 million, with approximately 722 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Animation of a man measuring a percentage sign, symbolising rising interest rates.
Share Market News

Here's when Westpac says the RBA will now cut interest rates

Will borrowers need to wait until the middle of next year for relief? Let's find out.

Read more »

Boys making faces and flexing.
Opinions

3 ASX 300 shares to buy and hold for the long run

I believe these stocks have loads of growth potential.

Read more »

Young girl drinking milk showing off muscles.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a great end to the trading week for ASX investors today.

Read more »

Hands reaching high for a trophy with a sunset in the background.
Record Highs

The ASX 200 Index is on its way to another all-time high today. Here's why

These blue chip stocks are driving the index towards a new record today...

Read more »

Group of friends trading stocks on their phones. symbolising the 3 most traded ASX 200 shares today
Share Market News

3 ASX mining stocks topping the most-traded list in October

Chinese stimulus news and company announcements likely contributed to the higher trading activity.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Share Gainers

3 ASX 200 stocks smashing the benchmark this week

These three ASX 200 stocks are leading the charge this week. Here’s how.

Read more »

Two people tired and resting after sports race.
Broker Notes

Fundie rates 2 ASX 200 stocks in short-term pain but with long-term gain potential

Blackwattle Investment Partners sees these 2 ASX 200 stocks as worthy of a buy and hold strategy.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why A2 Milk, EOS, GQG, and Mineral Resources shares are racing higher today

These shares are ending the week strongly. But why?

Read more »